ABSTRACT
Calcium channel blockers are potent vasodilators with antihypertensive, antianginal, and antiarrhythmic effects. All clinically available calcium channel blockers inhibit the L-type voltage-gated calcium channel, which results in relaxation of vascular smooth muscle and negative inotropic and chronotropic effects in the heart. Mibefradil, a calcium channel blocker that has been withdrawn from the market, blocks both L-type and T-type calcium channels with a greater selectivity for the T-type channels.
